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Abstract
Hormone decline is common to all women during aging and, associated with other factors, leads to cognitive impairment. Its 
replacement enhances cognitive performance, but not all women present a clinical and family or personal history that justifies 
its use, mainly women with a history of cancer. The aim of this study was to determine whether a daily oral dose of 80 mg of 
isoflavone extract for 4 months can produce benefits in women with low hormone levels, contributing to improvement in cognitive 
aspects. The sample comprised 50- to 65-year-old women whose menstruation had ceased at least 1 year before and who had 
not undergone hormone replacement. The volunteers were allocated to two groups of 19 individuals each, i.e., isoflavone and 
placebo. There was a weak correlation between menopause duration and low performance in the capacity to manipulate infor-
mation (central executive). We observed an increase in the capacity to integrate information in the group treated with isoflavone, 
but no improvement in the capacity to form new memories. We did not observe differences between groups in terms of signs 
and symptoms suggestive of depression according to the Geriatric Depression Scale. Our results point to a possible beneficial 
effect of isoflavone on some abilities of the central executive. These effects could also contribute to minimizing the impact of 
memory impairment. Further research based on controlled clinical trials is necessary to reach consistent conclusions. 
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Estrogen receptors affect several neurotransmission 
systems in many areas, including the catecholaminergic, 
serotoninergic and gabaergic ones, interfering with cognitive 
functioning. One of the actions of estrogen is to enhance 
the density of the dendritic spines in the neurons of the CA1 
area in the hippocampus (1). Progesterone contributes to 
the same action within 6-8 h of ingestion, and returns to 
basal levels rapidly (2). 
Estrogen increases the concentration of acetylcholine 
transferase, an enzyme that synthesizes acetylcholine, 
the neurotransmitter involved in memory functions. Fur-
thermore, neurotrophic effects of estrogen may explain 
how this hormone could have a protective action against 
cognitive deficit during aging (3,4). 
Hormone decline is common to all women during ag-
ing and, associated with other factors, leads to cognitive 
impairment, especially regarding memory. Its replacement 
enhances cognitive performance, but not all women present 
a clinical and family or personal history that justifies its use, 
mainly women with a history of cancer (5-7). 
Isoflavone is a compound present in soy with a chemical 
structure similar to that of estrogen, hence the interest in its 
use as an alternative substance to alleviate the effects of 
menopause (8). Even though several studies have shown 
the influence of isoflavone on cognitive performance, the 
results are still quite contradictory. A review by Zhao and 
Brinton (9) of the literature published between 2000 and 
2007 showed only seven studies that analyzed the ef-
fects of isoflavones on the cognition of postmenopausal 
women. Among the factors justifying the discrepancies in 
the results of different studies, the authors cite variations in 
the composition of phytoestrogen, length of administration, 
design of the studies and heterogeneity of the populations 
studied, suggesting the need for more randomized placebo-
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controlled studies.
The objective of the present study was to evaluate the 
effect of isoflavone on the cognition of post-menopausal 
women through a randomized placebo-controlled study 
conducted on a group of women having similar follicle- 
stimulating hormone (FSH) levels.
Material and Methods
Subjects
The inclusion criteria were 50- to 65-year-old women 
whose menstruation had ceased at least 1 year before and 
whose serum FSH concentrations were over 30 mIU/mL, 
and who had not undergone hormone therapy and were 
not taking any hypnotic medication. Volunteers with scores 
below 10 on the Geriatric Depression Scale were invited to 
participate in the study. Randomization was performed by a 
third researcher and patients were allocated to two groups 
of 19 individuals each, i.e., isoflavone and placebo groups. 
Treatment consisted of the ingestion of one pill a day over 
a period of 4 months. The tablets of Fisiogen® (provided by 
the Zambon Group, Italy) contained 80 mg isoflavone (60.8 
mg genistein, 16 mg daidzein, and 3.2 mg glycitein). The 
placebo group received similar pills, which did not contain 
the active pharmaceutical ingredient. After 4 months of 
treatment, the patients were submitted to the same clinical 
assessment. Patients had a monthly consultation, when 
medication for the subsequent month was supplied, and 
they were inquired as to their clinical complaints. 
The groups were matched for age (54.4 ± 4.3 and 56.6 
± 3.6 years, isoflavone and placebo, respectively), age 
at onset of menopause (48.3 ± 3.3 and 48.2 ± 5.3 years, 
isoflavone and placebo, respectively) and the duration of 
menopause (5.6 ± 4.6 and 8.2.6 ± 6.7 years, isoflavone 
and placebo, respectively).
Clinical assessment 
The following instruments were used for the cognitive 
evaluation: Visual-Spatial test; Digit span of the Wechsler 
Adult Intelligence Scale III (WAIS-III) to evaluate short-term 
memory and the capacity to manipulate information (central 
executive); Digit symbol (WAIS-III) to evaluate agility and 
attention; Similarity (WAIS-III) to evaluate the capacity to 
integrate information; Verbal Paired Associates (WMS-R) 
to evaluate the declarative episodic memory, integration of 
information and learning of verbal content (10); Geriatric 
Depression Scale (GDS) to evaluate depression (11).
The same examiner applied the tests and neuropsycho-
logical tests, being blind to the substances administered 
during the experiment. 
Statistical analysis
The Student t-test for independent samples was used 
to compare the groups before and after intervention and 
effect size to evaluate the degree of juxtaposition of the 
samples. The chi-square test was used to compare the 
number of volunteers in both groups who had not learned 
the tasks during the trials of the Verbal Paired Associates. 
The comparison of the number of recalls of the groups, 
considering the type of stimulus (with or without semantic 
relation) during the trials was performed by three-way 
ANOVA for repeated measures and by the Pearson test to 
evaluate possible correlations between parameters. Signifi-
cance was set at P < 0.05 and the Statistica 5.0 software 
was used for all analyses.
The research protocol was approved by the Ethics 
Committee of UNIFESP/EPM (Protocol #0564/02) and 
all subjects gave written informed consent to participate 
in the study.
Results
Although we controlled the variables that affect cognitive 
performance, after the code was opened up (double blind) 
we observed that, at baseline, the groups were significantly 
different in some cognitive variables, and this is the reason 
why we chose to use the delta in the final analysis. The 
analysis showed a negative correlation between menopause 
duration and the number of items recalled in the reverse 
order test of the Digit span (r = -0.37; P < 0.05).
We observed differences between the performance of 
the groups in semantically related pairs in the first and the 
second trials of the Verbal Paired Associates test and in 
the number of delayed recalls (P = 0.04; Table 1). The delta 
scores regarding the total number of words in the delayed 
recall showed statistically significant differences between 
groups only in the semantically non-related pairs, that is, 
the placebo group presented a decrease in the number of 
recalls while the experimental group presented no changes 
(P = 0.02). No differences were detected regarding the per-
formance in the Test of Free Recall of Word Pairs between 
the placebo and the isoflavone groups (P = 0.06). 
In terms of the number of volunteers per group who had 
not acquired the pairs of words along the trials, we found 
no statistically significant differences when we compared 
the pre- and post-treatment results for the placebo group. 
Discussion
Even though this was a randomized study, when it was 
over we realized that the groups were statistically differ-
ent in terms of cognitive and mood variables. Therefore, 
we decided to use the delta for the analysis of treatment 
effects. 
There was a weak correlation between menopause 
duration and low performance in the capacity to manipulate 
information (central executive). On the other hand, we ob-
served better results in the capacity to integrate information 
in the group treated with isoflavone (recall of semantically 
related words), but no improvement in the capacity to form 
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new memories (episodic declarative memory). These results 
agree with those obtained by other investigators (12-14). 
Our results point to a possible beneficial effect of 
isoflavone on some abilities of the central executive (e.g., 
manipulation and integration of information). These effects 
could also contribute to minimizing the impact of memory 
impairment. There was a possible stabilization of memory 
decay, i.e., recall capacity, but storing capacity remained 
limited. Barrett-Connor and Kritz-Silverstein (15) detected 
similar results. 
Finally, visual-spatial abilities did not present significant 
differences, as in the study of Ditkoff et al. (16) with hormone 
replacement therapy. 
The review of Lee et al. (17) evaluated the metabolism 
of soy isoflavones and their action on cognition function by 
mimicking the effects of estrogen on the central nervous 
system. Estrogen affects neuron survival and growth, 
synaptic plasticity and brain function through its antioxidant 
properties. Genistein and other soy isoflavones may act 
in a similar manner because they also exhibit estrogenic 
activity. Moreover, soy isoflavones stimulate the activity of 
choline acetyltransferase. The estrogenic effects of soy 
isoflavones appear to be dose dependent. However, the 
dose administered may not reflect the uptake by the central 
nervous system, since isoflavones in foods and supplements 
are highly water-soluble glucosides, and therefore have to 
be processed by intestinal β-glucosidases to release bioac-
tive aglycons (daidzein, genistein and glycitein). Daidzein 
needs to be further processed to release the estrogenic 
and biologically active metabolite, equol. Several studies 
have demonstrated wide variation in the intestinal metabo-
lism of soy isoflavones, regardless of the volunteers’ age, 
even when the dose is standardized (18). This variation 
may account for the divergent results in terms of cognitive 
improvement reported in the literature. 
Considering these conflicting results in the literature, 
further research based on controlled clinical trials is neces-
sary to yield consistent conclusions. 
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Table 1. Comparison of the delta scores between groups regarding cognitive variables.
 Placebo Isoflavone
 Mean SD Mean SD
Visual-spatial test 0.1 1.1 -0.1 2.3
GDS -5.1 5.9 -2.7 5.2
WAIS-III
Digit symbol 1.5 8.0 2.6 7.4
Digit forward -0.2 1.0 -0.2 1.1
Digit backward 0.5 1.1 0.9 1.4
Similarity 0.2 3.4 1.3 3.5
Verbal Paired Associates - WMS-R
With semantic relation
Trial 1 0.8 1.1 1.6* 1.1
Trial 2 0.2 1.0 1.3* 1.2
Delayed recall 0.1 0.2 0.4 0.7
Without semantic relation
Trial 1 0.8 1.1 0.5 0.5
Trial 2 1.0 1.9 0.6 0.8
Delayed recall 0 0.9 1.2* 1.6
Learning word pairs
Difference in the number of items recalled from the 1st to the 
2nd trial in the semantically related pairs
-0.1 0.3 0.1 0.5
Difference in the number of items recalled from the 1st to the 
2nd trial in the pairs without semantic relation 
-1.0 1.4 0.3 1.3
GDS = Geriatric Depression Scale; WAIS-III = Wechsler Adult Intelligence Scale III. *P < 0.05, 
isoflavone compared to placebo (Student t-test for independent samples).
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